Cargando…

Significance of upfront cytoreductive nephrectomy stratified by IMDC risk for metastatic renal cell carcinoma in targeted therapy era – a multi-institutional retrospective study

BACKGROUND: This retrospective multicenter study aimed to evaluate the survival benefit of upfront cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (RCC) patients stratified by International Metastatic RCC Database Consortium (IMDC) risk criteria. METHODS: We reviewed the medical re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kato, Renpei, Naito, Sei, Numakura, Kazuyuki, Hatakeyama, Shingo, Koguchi, Tomoyuki, Kojima, Takahiro, Kawasaki, Yoshihide, Kandori, Shuya, Kawamura, Sadafumi, Arai, Yoichi, Ito, Akihiro, Nishiyama, Hiroyuki, Kojima, Yoshiyuki, Ohyama, Chikara, Habuchi, Tomonori, Tsuchiya, Norihiko, Obara, Wataru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Nature Singapore 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8882566/ https://www.ncbi.nlm.nih.gov/pubmed/34973106 http://dx.doi.org/10.1007/s10147-021-02091-8

Ejemplares similares

Correction to: Significance of upfront cytoreductive nephrectomy stratified by IMDC risk for metastatic renal cell carcinoma in targeted therapy era – a multi‑institutional retrospective study
por: Kato, Renpei, et al.
Publicado: (2023)

Outcomes of axitinib versus sunitinib as first‐line therapy to patients with metastatic renal cell carcinoma in the immune‐oncology era
por: Numakura, Kazuyuki, et al.
Publicado: (2021)

Clinical impact of early response to first‐line VEGFR‐TKI in patients with metastatic renal cell carcinoma on survival: A multi‐institutional retrospective study
por: Sobu, Ryuta, et al.
Publicado: (2022)

Impact of pretreatment anemia on upfront abiraterone acetate therapy for metastatic hormone-sensitive prostate cancer: a multicenter retrospective study
por: Okamoto, Teppei, et al.
Publicado: (2021)

Impact of germline HLA genotypes on clinical outcomes in patients with urothelial cancer treated with pembrolizumab
por: Takahashi, Shuhei, et al.
Publicado: (2022)

Host-related Risk Factors for Adherent Perinephric Fat in Healthy Individuals Undergoing Laparoscopic Living-donor Nephrectomy
por: Narita, Shintaro, et al.
Publicado: (2017)

Cytoreductive Nephrectomy in 2021: Obsolete
por: Meza, Luis, et al.
Publicado: (2021)

New Paradigms for Cytoreductive Nephrectomy
por: Lichtbroun, Benjamin J., et al.
Publicado: (2022)

Cytoreductive Nephrectomy and Nephrectomy/Complete Metastasectomy for Metastatic Renal Cancer
por: Russo, Paul, et al.
Publicado: (2007)

Cytoreductive nephrectomy in the current treatment algorithm
por: Kuusk, Teele, et al.
Publicado: (2019)

Cytoreductive Nephrectomy in 2021: Obsolete but Necessary
por: Capitanio, Umberto, et al.
Publicado: (2021)

Cytoreductive Nephrectomy: Still Necessary in 2021
por: Méjean, Arnaud, et al.
Publicado: (2022)

Comparison of upfront versus deferred cytoreductive nephrectomy in patients with metastatic renal cell carcinoma receiving systemic therapy: a systematic review and meta-analysis
por: Li, Kun-peng, et al.
Publicado: (2023)

Insulin-like growth factor-1 genotypes and haplotypes influence the survival of prostate cancer patients with bone metastasis at initial diagnosis
por: Tsuchiya, Norihiko, et al.
Publicado: (2013)

Factors influencing warm ischemia time in robot-assisted partial nephrectomy change depending on the surgeon’s experience
por: Numakura, Kazuyuki, et al.
Publicado: (2022)

Comprehensive characterization of the perioperative morbidity of cytoreductive nephrectomy
por: Leone, Andrew, et al.
Publicado: (2016)

PNI as a Potential Add-On Biomarker to Improve the IMDC Intermediate Prognostic Score
por: Bayoğlu, İbrahim Vedat, et al.
Publicado: (2023)

Erratum to comprehensive characterization of the perioperative morbidity of cytoreductive nephrectomy
Publicado: (2016)

Cytoreductive nephrectomy in the age of immunotherapy-based combination treatment
por: Song, Sang Hun, et al.
Publicado: (2023)

Therapeutic effects of the combined androgen blockade therapy versus luteinizing hormone-releasing hormone analog monotherapy in patients with hormone naïve metastatic prostate cancer: a multi-institutional comparative analysis
por: Narita, Takuma, et al.
Publicado: (2021)

The current role of cytoreductive nephrectomy for metastatic renal cell carcinoma
por: Umbreit, Eric C., et al.
Publicado: (2021)

The Evolving Landscape of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma
por: Studentova, Hana, et al.
Publicado: (2023)

Successful mammalian target of rapamycin inhibitor maintenance therapy following induction chemotherapy with gemcitabine and doxorubicin for metastatic sarcomatoid renal cell carcinoma
por: NUMAKURA, KAZUYUKI, et al.
Publicado: (2014)

Incidence, Etiology, Prevention and Management of Ureteroenteric Strictures after Robot-Assisted Radical Cystectomy: A Review of Published Evidence and Personal Experience
por: Narita, Shintaro, et al.
Publicado: (2021)

Complete remission of brain metastases in renal cell carcinoma treated with axitinib after failure with nivolumab and ipilimumab treatment
por: Takayama, Koichiro, et al.
Publicado: (2022)

Deliberation on Deferred Cytoreductive Nephrectomy and Postoperative Treatment for Advanced Renal Cell Carcinoma: A Case Report
por: Nakagawa, Takuya, et al.
Publicado: (2022)

Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk localized prostate cancer
por: Narita, Shintaro, et al.
Publicado: (2012)

First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC
por: Ko, J J, et al.
Publicado: (2014)

Laparoscopic cytoreductive nephrectomy and adrenalectomy for metachronous RCC metastases—Case report
por: Petrut, Bogdan, et al.
Publicado: (2020)

Complications associated with perioperative use of tyrosine kinase inhibitor in cytoreductive nephrectomy
por: Carvalho, Filipe L. F., et al.
Publicado: (2019)

The role of cytoreductive nephrectomy in renal cell carcinoma patients with liver metastasis
por: Guo, Boda, et al.
Publicado: (2021)

Clinical implications of serum N‐glycan profiling as a diagnostic and prognostic biomarker in germ‐cell tumors
por: Narita, Takuma, et al.
Publicado: (2017)

Impact of Early Exposure to Simulation Program on Undergraduate Medical Students’ Interest in Urology
por: Kimura, Tomokazu, et al.
Publicado: (2021)

Severe Immune-Related Adverse Events in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma Are Associated with PDCD1 Polymorphism
por: Kobayashi, Mizuki, et al.
Publicado: (2022)

Prognostic significance of early changes in serum biomarker levels in patients with newly diagnosed metastatic prostate cancer
por: Narita, Shintaro, et al.
Publicado: (2019)

Changes in conditional net survival and dynamic prognostic factors in patients with newly diagnosed metastatic prostate cancer initially treated with androgen deprivation therapy
por: Narita, Shintaro, et al.
Publicado: (2019)

Is Cytoreductive Nephrectomy Still a Standard of Care in Metastatic Renal Cell Carcinoma?
por: Renner, Alex, et al.
Publicado: (2019)

The Effect of Cytoreductive Partial Nephrectomy in Elderly Patients with Metastatic Renal Cell Carcinoma
por: Chen, Jiabi, et al.
Publicado: (2020)

Predictors of Cytoreductive Nephrectomy for Metastatic Kidney Cancer in SEER and Metropolitan Detroit Databases
por: Vaishampayan, Ulka, et al.
Publicado: (2019)

Cytoreductive Nephrectomy and Metastatic Renal Cell Carcinoma: State of the Art and Future Perspectives
por: Napolitano, Luigi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_snan8op06unlf4e801mia5i8f0